Posted on 2/4/19
4 Things You Need to Know About Merck's Q4 Earnings Results
Merck (NYSE:MRK) topped analysts' consensus earnings estimates every time the company reported quarterly results in 2018. That's one of the reasons why Merck's share price soared . . .
Posted on 2/4/19
Pfizer's Next 3 Years: What Investors Can Expect
Pfizer (NYSE:PFE) delivered one of its strongest performances in a long time last year. Its stock jumped more than 20% in 2018, handily beating the broader . . .
Posted on 2/1/19
Outlook Therapeutics Closes Final Tranche of $20 Million Private Placement
CRANBURY, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that it closed on the final tranche (of four) of its $20.0 . . .
Posted on 2/1/19
AmerisourceBergen Corporation (ABC) CEO Steven Collins on Q1 2019 Results - Earnings Call Transcript
Subscribers OnlyEarning Call AudioABC) Q1 2019 Results Earnings Conference Call January 31, 2019 8:30 AM ETCompany ParticipantsBennett Murphy - Vice President, Investor Relations.Steven Collis - Chairman . . .
Posted on 2/1/19
Cancer Genetics Announces Closing of Public Offering of Common Stock
RUTHERFORD, N.J., Jan. 31, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular . . .
Posted on 1/31/19
Hitachi Chemical To Acquire apceth Biopharma GmbH
Hitachi Chemical Advanced Therapeutics Solutions, LLC announces an agreement by which apceth Biopharma GmbH, a contract manufacturer of cell and gene therapy products
Posted on 1/31/19
Pfizer: Strong Buy Heading Into 2019
Summary Pfizer reported their fourth-quarter earnings for 2018 yesterday before the market opened, beating analyst expectations narrowly for both revenue and EPS. Poor guidance which fell . . .
Posted on 1/31/19
3 Big Pharmas Expecting a Softer 2019
Johnson & Johnson (NYSE:JNJ) kicked off this earnings season with a grim outlook for its pharmaceutical business, and it looks like the trouble has spread to . . .
Posted on 1/30/19
Trevena Announces $10M Stock Offering
CHESTERBROOK, Pa., Jan. 30, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) today announced that it entered into securities purchase agreements with two healthcare-focused institutional investors, . . .
Posted on 1/30/19
Celgene: Long The Deal Spread
Summary BMY is acquiring CELG in a stock and cash deal currently valued at $98.93 for each share of CELG plus an earn-out worth $9 per . . .
Posted on 1/30/19
Pfizer Q4 Earnings Update: 4 Key Things You Need to Know
You know there was some bad news with a company's quarterly update when the stock drops after the results are announced. That's what happened Tuesday morning . . .
Posted on 1/30/19
Better Buy: Johnson & Johnson vs. Pfizer
Healthcare has given investors great opportunities for a long while, and pharmaceutical specialists in particular have seen plenty of solid gains over time. For Johnson & . . .
Posted on 1/29/19
Cancer Genetics Announces Proposed Public Offering of Common Stock
RUTHERFORD, N.J., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), a leader in enabling precision medicine for immuno-oncology and genomic medicine through molecular . . .
Posted on 1/28/19
For the Fifth Consecutive Year, Aramark Named a Top 50 Employer for People with Disabilities
PHILADELPHIA--(BUSINESS WIRE)--Aramark (NYSE:ARMK), a global leader in food, facilities management and uniforms, who employs 270,000 team members across the globe, has again been named a Top . . .
Posted on 1/28/19
BMS Reports Q4: Analysis Of Its Stock And Of Celgene
Summary Bristol-Myers Squibb reported a solid Q4 and pretty good guidance for 2019, but revenue growth is slowing. In that context and given poor new drug . . .
Posted on 1/28/19
3 Things You Should Expect in Pfizer's Q4 Earnings Update
Pfizer (NYSE:PFE) gave good news and bad news when it reported third-quarter results in October. The big drugmaker beat Wall Street's earnings estimates, but it missed . . .
Posted on 1/27/19
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on January 22, 2019 it approved non-statutory stock options to purchase an aggregate of 170,050 shares of its . . .
Posted on 1/27/19
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
RADNOR, Pa., Jan. 25, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and . . .
Posted on 1/25/19
Covered-Call Writing With J&J
Summary Covered-call writing is one of my favorite strategies to generate monthly income while mitigating downside risk. J&J is a perfect stock to write calls against. . . .
Posted on 1/25/19
Johnson & Johnson: Goodbye Growth
Summary Johnson & Johnson has seen a real growth slowdown at the end of 2018. Investors should embrace themselves for lower growth in 2019 as well. . . .
Posted on 1/25/19
Does Johnson & Johnson's Grim Outlook Spell Trouble for Big Pharma Stocks?
Every January, Johnson & Johnson (NYSE:JNJ) executives share their expectations for the year ahead, and this year investors didn't like what they heard. The company isn't . . .
Posted on 1/24/19
Johnson & Johnson (JNJ) Q4 2018 Earnings Conference Call Transcript
IMAGE SOURCE: THE MOTLEY FOOL.Johnson & Johnson (NYSE:JNJ) Q4 2018 Earnings Conference CallJan. 22, 2019 8:30 a.m. ETContents:Prepared RemarksQuestions and AnswersCall ParticipantsPrepared Remarks:OperatorGood morning. Welcome to . . .
Posted on 1/24/19
Better Buy: Amgen vs. Johnson & Johnson
Johnson & Johnson (NYSE:JNJ) and Amgen (NASDAQ:AMGN) are two of the most important healthcare companies on the planet. Both companies are massive, highly profitable, and have . . .
Posted on 1/23/19
PTC Therapeutics Announces Pricing of Public Offering of Common Stock
PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 6,720,000 shares of its common stock at a public offering price of . . .
Posted on 1/23/19
Talee Bio Announces $4.5 Million Award from the Cystic Fibrosis Foundation
Talee Bio, Inc., a development stage biopharmaceutical company focused on developing gene therapy treatments for cystic fibrosis, today announced agreements

